Immunotherapy Archives

Interview 10 May 2017

Video: Meet the CEO fighting Cancer with Mycobacteria

Clara talked to Linda Summerton, CEO of Immodulon Therapeutics, about the company’s project of applying the microbiome to immuno-oncology. As R&D efforts in the microbiome gain traction, Clara talked to the head of one of the most valuable companies in the UK, Immodulon Therapeutics. When asked about Forbes’ valuation of her company at £400M, Linda Summerton laughed, “That’s […]

May 10, 2017 - 3 minutesmins - By Evelyn Warner

GammaDelta Therapeutics Takeda Collaboration 1

More News! 9 May 2017

British Biotech Startup Partners with Takeda to Advance its T Cell Platform

GammaDelta Therapeutics and Takeda have formed a strategic collaboration to develop a novel T cell platform, which is based on gamma delta (γδ) T cells. Based in London, GammaDelta Therapeutics builds on the work of Adrian Hayday and Oliver Nussbaumer of Kings College London and The Francis Crick Institute. Backed by the huge British VC […]

May 9, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 8 May 2017

The EU Approves New Treatment for a Rare Pediatric Cancer

Update (08/05/2017): The European Commission has granted marketing authorization to Apeiron Biologic’s APN311 in the rare pediatric cancer neuroblastoma. Originally published on 27/03/2017 Apeiron Biologics has announced that the EMA’s CHMP has recommended the approval of APN311 for immunotherapy of high-risk neuroblastoma. Apeiron Biologics is a Vienna-based biotech company developing immunological approaches to treat cancer. […]

May 8, 2017 - 3 minutesmins - By Melanie De Almeida

Immunocore GSK Immuno oncology collaboration

News and Trends 8 May 2017

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Immunocore has singled out a new lead candidate in its immuno-oncology discovery program with GSK, triggering an undisclosed milestone payment to Immunocore. Based in Oxford, Immunocore is one of the hottest biotechs in the immuno-oncology space, which was able to raise one of the largest European private funding rounds ever (€300M) and is backed by […]

May 8, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 3 May 2017

Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy

Rigontec has announced the start if its first-in-human Phase I/II study with its pioneering RNA-based candidate, RGT100, in solid tumors and lymphoma. Rigontec, based in Munich, is exploring RNA’s applications in immuno-oncology. Since the company was founded in 2014, it has raked in an impressive €30M in series A funding. Now, only 3 years later, the biotech is […]

May 3, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 3 May 2017

New Immuno-oncology Biotech Gets a €20M Series A Funding Boost

Imcheck Therapeutics from Marseille has just completed a €20M Series A funding round, backed by big investors like the Boehringer Ingelheim Venture Fund (BIVF). The French biotech Imcheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute (IPC) in Marseille and is developing next-generation immunomodulatory antibodies for the treatment of cancer and autoimmune diseases. […]

May 3, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 3 May 2017

Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?

As immunotherapies are moving from large academic centers to clinics across the world, doctors are realizing that releasing the breaks of the immune system comes with serious risks – and that research on its adverse effects is lagging behind. This week, AstraZeneca’s anti-PD-L1 antibody durvalumab received FDA approval to treat patients with metastatic urothelial carcinoma, making […]

May 3, 2017 - 4 minutesmins - By Melanie De Almeida

News and Trends 2 May 2017

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Despite a recent public dispute with its key rival Cellectis regarding the validity of Celyad’s US patents, Novartis has now entered a non-exclusive […]

May 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 26 Apr 2017

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, […]

April 26, 2017 - 1 minutemin - By Melanie De Almeida

News and Trends 20 Apr 2017

Norway Brings Another Cancer Vaccine to the Clinic

Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell division and are a key driver of cancer progression and treatment resistance. The Norwegian biotech Targovax is developing peptide-based anti-cancer vaccines targeting these mutations found […]

April 20, 2017 - 3 minutesmins - By Melanie De Almeida

Interview 20 Apr 2017

Which EU Immuno-Oncology Company are you Cheering for?

Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one do you think is doing it best? The field of immuno-oncology is overcrowded, and there’s plenty of companies pushing to make their cutting-edge technology a […]

April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 19 Apr 2017

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

UPDATE (19/04/2017): CTL019 has been granted Breakthrough Designation by the FDA for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Novartis and Kite have been in a tight race to bring the first CAR-T therapy to market: Novartis has staked out acute lymphoblastic leukemia (ALL) while Kite has gone for DLBCL. With this “tacit endorsement,” Novartis is encroaching on […]

April 19, 2017 - 3 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Video: Meet the CEO fighting Cancer with Mycobacteria

British Biotech Startup Partners with Takeda to Advance its T Cell Platform

The EU Approves New Treatment for a Rare Pediatric Cancer

Immunocore Boosts its Collaboration with GSK with new Lead Compound

Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy

New Immuno-oncology Biotech Gets a €20M Series A Funding Boost

Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Norway Brings Another Cancer Vaccine to the Clinic

Which EU Immuno-Oncology Company are you Cheering for?

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!